Coloplast Bladder Mesh Lawsuit
Update Spring 2023 – We are accepting Coloplast sling and pelvic mesh removal/revision cases.
$2.5 Million Verdict
Coloplast Bladder Mesh lawsuit resulted in a $2.5 million verdict in April 2022.
Coloplast sling and pelvic mesh lawsuits continue being filed in 2023 and some earlier cases are beginning the settlement process. Since 2011, when the pelvic mesh litigation began, we have successfully prosecuted cases for women implanted with transvaginal mesh products that have been surgically removed or revised.
Coloplast Bladder Sling and Pelvic Mesh Products
We are reviewing cases involving Coloplast pelvic mesh and bladder sling products that required surgical revision or removal including:
- Altis Transobturator Sling
- Aris Transobturator Sling System
- Supris Suprapubic Sling System
- Novasilk Synthetic Flat Mesh
- Suspend-Tutoplast Processed Fascia Lata
- Exair-Prolapse Repair System
- Axis-Tutoplast Processed Dermis
- Restorelle
- Smartmesh
- Omnisure
- Minitape
Women plaintiffs implanted with bladder sling and pelvic mesh products claim that the vaginal mesh devices cause serious injuries, including:
- Vaginal mesh erosion: polypropylene mesh can break down, leaving the mesh exposed to protrude through the vagina.
- Erosion of mesh into other organs: polypropylene mesh may erode into the urethra, bladder or rectum.
- Vaginal mesh contraction: polypropylene mesh shortens and tightens to cause vaginal tissue pain.
- Pain during sexual intercourse
- Urinary problems
- Infections
- Bleeding
- Reoccurrence
- Emotional issues
- Chronic pain
- Fistulas
- Organ perforation
- Incontinence
- Pelvic nerve damage
Pelvic mesh and bladder sling problems have been reported by major medical clinics for decades. Major medical clinics and university affiliated medical institutions, including the Cleveland Clinic, have published articles and treatise for your review at Mesh Problems and Complications.
Contact us now for a free medical legal consultation about your pelvic mesh product at 1-800-814-4540. There are deadlines in each state and hospitals destroy medical record evidence after a certain time period, so contact us now.
Pelvic Mesh Verdicts
Verdicts, settlements, manufacturers, products, and jurisdictions follows:
- 7/12: $5.5 million – Christine Scott – C.R. Bard (Avaulta Plus) – CA
- 2/13: $11.11 million – Linda Gross – Ethicon/JJ (Prolift) – NJ
- 8/13: $2 million – Donna Cisson – C.R. Bard (Avaulta) – MDL WV
- 2/14: $0 – Carolyn Lewis – Ethicon/JJ (TVT-O) – MDL WV
- 4/14: $1.2 million – Linda Batiste – Ethicon/JJ (TVT-O) – TX
- 7/14: $0 – Diane Albright – Boston Scientific (Pinnacle) – MA
- 8/14: $0 – Maria Cardenas – Boston Scientific (Obtryx) – MA
- 9/14: $3.27 million – Jo Huskey – Ethicon/JJ (TVT-O) – MDL WV
- 9/14: $73.465 million – Martha Salazar – Boston Scientific (Obtryx) – TX
- 11/14: $6.7+ million – Amal Eghnayem – Boston Scientific (Pinnacle) – MDL FL
- 11/14: $6.7+ million – Margarita Dotres – Boston Scientific (Pinnacle) – MDL FL
- 11/14: $6.7+ million – Mania Nunez – Boston Scientific (Pinnacle) – MDL FL
- 11/14: $6.5+ million – Juana Betancourt – Boston Scientific (Pinnacle) – MDL FL
- 11/14: $5.25 million – Jeanie Blankenship – Boston Scientific (Obtryx) – MDL WV
- 11/14: $4.75 million – Chris Wilson – Boston Scientific (Obtryx) – MDL
- 11/14: $4.25 million – Carol Campbell – Boston Scientific (Obtryx) – MDL
- 11/14: $4.25 million – Jacquelyn Tyree – Boston Scientific (Obtryx) – MDL
- 2/15: Settled – Wise v. Bard – MDL
- 3/15: Settled – Bellew v. Ethicon (Prolift) – MDL;
- 5/15: Settled – Sanchez v. Boston Scientific (Pinnacle) – CA
- 3/15: $5.7 million – Coleen Perry – Ethicon/JJ Abbrevo sling – CA
- 5/15: $100 million – Deborah Barda v. Boston Scientific (Pinnacle, Advantage Fit) – DL
- 10/15: $0 – Carol Cavness v. Ethicon/JJ (Prosima) – TX
- 10/15: $0 – Martha Carlson v. Boston Scientific (Uphold) – NC
- 12/15: $12.5 million – Hammons v. Ethicon/JJ (Prolift) – PA
- 2/16: $0 – Sherrer v. Boston Scientific (Solyx) and Bard (Align) – MO
- 2/16: $13.5 – Carlino v. Ethicon/JJ (TVT) – PA
- 4/17: $20.0 million – Engleman v. Ethicon/JJ (TVT Secur) – PA
- 5/17: $2.16 million – Betz v. Ethicon/JJ (Prolift) – PA
- 9/17: $57.1 million – Ebaugh v. Ethicon/JJ (TVT-Secur) – PA
- 3/18: $35 million – Kaiser v. Ethicon/JJ (Prolift) – IN
- 4/18: $68 million – McGinnis v. Bard (Align and Avaulta) – NJ
- 1/19: $41 million – Emmett v. Ethicon/JJ (Gynemesh, Prolift, TVT-O) – PA
- 4/19: $120 million – McFarland v. Ethicon/JJ (TVT-O) – PA
- 5/19: $80+ million – Mesigian v. Ethicon/JJ (Prolift) – PA
- 6/19: $500,000 – Dunfee v. Ethicon/JJ (Prolift) – PA
- 4/22 $2.5 million – Redding v. Coloplast (Novasilk) – FL
- 3/22: 0 – Shears v. Ethicon/JJ (TVT) – WV
- 4/22: $2.5 million – Redding v. Coloplast (Novasilk) – FL
- 7/22: 0 – Burris v. Ethicon/JJ (Prolift, TVT-Secur) – OH
- 10/22: 0 – Jarrett v. Ethicon/JJ (TVT-O) – AR
- 10/22: 0 – Richards v. Ethicon/JJ (TVT-O) – TX
- 12/22: 0 – Snowden v. Ethicon/JJ (Abbrevo) – TX
FDA Warnings
July 2011: An FDA Safety Communication identified concerns and issued new recommendations on surgical mesh for transvaginal repair of Pelvic Organ Prolapse (POP).
September 2011: The FDA convened a public meeting of the Obstetrics and Gynecology Devices Panel to discuss the benefits and risks of the mesh use. The FDA issued 131 orders to conduct post market surveillance studies (PMAs) to 34 manufacturers of surgical mesh for transvaginal repair of POP. Most manufacturers elected to stop marketing surgical mesh.
January 2016: The FDA completed its reclassification of surgical mesh for transvaginal repair of POP into the highest risk class of devices (class III), which requires premarket approval (PMA) applications, the agency’s most stringent device review pathway, in order to stay on the market.
July 5, 2018: Manufacturers that did not file PMAs for their POP mesh by this deadline had to withdraw their products from the market.
February 12, 2019: The FDA convened an advisory committee meeting to share the available evidence and seek expert opinions on how to evaluate the risks and benefits of these devices. Boston Scientific filed two PMAs for its devices, the Uphold LITE Vaginal Support System and the Xenform Soft Tissue Repair System. Coloplast filed a PMA for its device, Restorelle DirectFix Anterior.
In February 2019, the FDA convened a panel of experts and agreed with their recommendations, but the FDA decided not to approve Pelvic Organ Prolapse devices. Even though these products can no longer be used in patients, Boston Scientific and Coloplast are required to continue follow up of the subjects already enrolled in their 522 studies.
Since 2019, some of the Boston Scientific mesh products had been removed from the market and are no longer being implanted in women. However, thousands of women still have Coloplast implants – Altis Sling, Aris Sling, Spris Sling, Novasilk mesh, Tutoplast, Exair, Axis Tutoplast, Restorelle, Smartmesh, Omnisure or Minitape – implanted and are still indwelling. Many ladies may experience complications and their surgeons may advise to have the implant surgically removed or revised.
Call us for your free medical legal consultation at 1-800-814-4540 or fill out the Contact Us Form and tell us about your claim.